Fasting Study of Alprazolam Extended-Release Tablets 3 mg to Xanax XR® Tablets 3 mg
Status:
Completed
Trial end date:
2004-08-01
Target enrollment:
Participant gender:
Summary
The objective of this study was to investigate the bioequivalence of Mylan's alprazolam 3 mg
Extended-release tablets to Pharmacia & Upjohn's Xanax XR® 3 mg tablets following a single,
oral 3 mg (1 x 3 mg) dose administered under fasting conditions.